Hypertension
HTN · CVRM · 2 drugs · 3 indications
Elevated blood pressure. Includes treatment-resistant hypertension.
Competitive Landscape (2 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| baxdrostat | AZN | Aldosterone synthase inhibitor | Small molecule | ORAL | FILED |
| Zilebesiran | AZN, ALNY | Angiotensinogen silencing | siRNA | SC | PHASE3 |
Indications (3)
Uncontrolled hypertension
Treatment-resistant hypertension
Upcoming Catalysts
Baxdrostat - Hypertension - FDA ApprovalREGULATORY
AZNQ2 2026
Zilebesiran - Hypertension - Ph3 - ToplineCLINICAL
ROG.SW2027
Data from Supabase · Updated 2026-03-24